Effectiveness of a Pharmacist‐Based Smoking‐Cessation Program and Its Impact on Quality of Life

Zillich, Alan J.; Ryan, Melody; Adams, Aimee; Yeager, Bryan F.; Farris, Karen B.

doi:10.1592/phco.22.9.759.34073

Cited by 71 publications

(55 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is also consistent with results suggested by Tonnesen where a 1-year abstinence rate of 25% should be expected from a smoking cessation programme 6 . While most of the studies showed a decrease in abstinence rate over time [11][12][13][14][15] , our study demonstrated a significant increase (P<0.05) in abstinence rate from clinic completion (19.8%) to both 6-(23.8%) and 12-month (25.4%) followup. This is consistent with the results found by Philbrick and colleagues who reported an increase in abstinence rate from 47.6% to 52.4% at 3 and 6 months respectively 16 and also the pilot study performed in CGH previously 7 .…”

Section: Discussioncontrasting

confidence: 65%

A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities

Poh¹,

Ng²

2016

Tob. Prev. Cessation

View full text Add to dashboard Cite

INTRODUCTION Smoking cessation clinic (SCC) was introduced into Singapore's healthcare setting to combat the increase in smoking prevalence. This study aims to determine (1)the effectiveness of a pharmacist-managed SCC, and (2)the association between abstinence rates and different treatment modalities, in Changi General Hospital. METHODS 445 patients who had attended the SCC were retrospectively reviewed. These patients received structured smoking cessation counselling with or without additional cessation aid comprising of nicotine replacement therapy (NRT), varenicline or bupropion. The study end points were point-prevalence abstinence rates (1)for all subjects, and (2)associated with various treatment modalities, at the final SCC review, 6-and 12-month follow-up. RESULTS The point-prevalence abstinence rates for all patients at completion of SCC review, 6-and 12-month follow-up were 19.8%, 23.8% (p=0.033), and 25.4% (p=0.009), respectively. Abstinence rates between 6-and 12-month follow-up were not statistically different. A significant association between abstinence rates and the use of pharmacotherapy was detected at 6-months' follow-up (p=0.005), but not at SCC review completion or 12-months' follow-up (p>0.05). Abstinence rates were highest at 6-and 12-month with use of varenicline (37.4% and 34.3%, respectively) followed by combination NRT (21.7% and 26.1%). Furthermore, patients who had received only smoking cessation counselling had abstinence rates of 20.7% and 26.0% at 6-and 12-month follow-up. CONCLUSIONS Patient participation in a pharmacist-managed SCC was associated with significantly improved abstinence rates at 6-and 12-months following programme completion. The use of pharmacotherapy was significantly associated with overall abstinence rates at 6-months' followup with varenicline appearing as the most effective smoking cessation aid.

show abstract

Section: Discussioncontrasting

confidence: 65%

A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities

Poh¹,

Ng²

2016

Tob. Prev. Cessation

View full text Add to dashboard Cite

show abstract

“…49 Furthermore, smoking cessation programs using behavioral modification along with bupropion or nicotine replacement have resulted in improved physical healthand mental health-related quality of life. 49,61 Therefore, we encourage a comprehensive smoking cessation program in patients with chordoma who are current smokers at the time of diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Determinants of quality of life in patients with skull base chordoma

Diaz

Maggacis

Zhang

et al. 2014

JNS

View full text Add to dashboard Cite

Object Skull base chordomas can be managed by surgical intervention and adjuvant radiotherapy. As survival for this disease increases, identification of determinants of quality of life becomes an important focus for guiding comprehensive patient care. In this study the authors sought to measure functional outcome and quality of life in patients with skull base chordomas and to identify determinants of quality of life in these patients. Methods The authors carried out an internet-based cross-sectional survey, collecting detailed data for 83 individual patients. Demographic and clinical variables were evaluated. Functional outcomes were determined by Karnofsky Performance Scale (KPS) and Glasgow Outcome Scale Extended (GOSE), quality of life was measured using the 36-Item Short Form Health Survey (SF-36), and depression was assessed using Patient Health Questions–9 (PHQ-9) instrument. Caregiver burden was assessed using the Zarit Burden Interview (ZBI). Univariate and multivariate analysis was performed to identify determinants of the physical and mental components of the SF-36. Results Patients with skull base chordomas who have undergone surgery and/or radiation treatment had a median KPS score of 90 (range 10–100, IQR 10) and a median GOSE score of 8 (range 2–8, IQR 3). The mean SF-36 Physical Component Summary score (± SD) was 43.6 ± 11.8, the mean Mental Component Summary score was 44.2 ±12.6, and both were significantly lower than norms for the general US population (p < 0.001). The median PHQ-9 score was 5 (range 0–27, IQR 8). A PHQ-9 score of 10 or greater, indicating moderate to severe depression, was observed in 29% of patients. The median ZBI score was 12 (range 0–27, IQR 11), indicating a low burden. Neurological deficit, use of pain medication, and requirement for corticosteroids were found to be associated with worse SF-36 Physical Component Summary score, while higher levels of depression (higher PHQ-9 score) correlated with worse SF-36 Mental Component Summary score. Conclusions Patients with skull base chordomas have a lower quality of life than the general US population. The most significant determinants of quality of life in the posttreatment phase in this patient population were neurological deficits (sensory deficit and bowel/bladder dysfunction), pain medication use, corticosteroid use, and levels of depression as scored by PHQ-9.

show abstract

“…390 This program consisted of nicotine replacement therapy (gum or transdermal patch) and 1-hour, pharmacist-facilitated counseling and behavior modification sessions offered to 31 self-referred patients during 12 weeks. Abstinence rates at 3 and 6 months were 42% and 26%, respectively.…”

Section: Documented Impactmentioning

confidence: 99%

Healthy People 2010: Challenges, Opportunities, and a Call to Action for America's Pharmacists

et al. 2004

View full text Add to dashboard Cite

Effectiveness of a Pharmacist‐Based Smoking‐Cessation Program and Its Impact on Quality of Life

Cited by 71 publications

References 34 publications

A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities

A 4-year Follow-up Evaluation Of A Pharmacist-managed Smoking Cessation Programme With Emphasis On Effectiveness Of Different Treatment Modalities

Determinants of quality of life in patients with skull base chordoma

Healthy People 2010: Challenges, Opportunities, and a Call to Action for America's Pharmacists

Contact Info

Product

Resources

About